Class Action Lawsuit Filed Against Soleno Therapeutics Over Alleged Securities Fraud
A class action lawsuit has been filed against Soleno Therapeutics (NASDAQ: SLNO) alleging securities fraud and unlawful business practices. The lawsuit follows a series of negative events, including a report questioning the safety and pricing of Soleno's drug DCCR, a patient death linked to the drug, and increased discontinuation rates. These events led to significant drops in Soleno's stock price.
Tickers: $SLNO
Topics: class action product safety regulatory filing securities fraud stock price decline